CompletedPhase 2

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

United States, Australia, Netherlands20 participantsStarted 2023-01-26

Plain-language summary

AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subject ≥ 18 years
. TGCT with only 1 joint involvement
. Symptomatic Measurable disease of at least 1 cm based on RECIST v1.1
. Stable prescription of analgesic regimen
. Agrees to follow contraception guidelines
. Women of childbearing potential must have a negative pregnancy test
. Adequate hematologic, hepatic, and renal function

Exclusion criteria

. Prior investigational drug use within 4 weeks or 5 half-lives of Baseline
. Previous use of therapeutics targeting CSF1 or CSF1R or oral tyrosine kinase inhibitors within 3 months prior to Baseline
. History of extensive or reconstructive surgery on the affected joint
. Active cancer (either currently or within 3 mo before Baseline) that requires/required therapy (e.g., surgery, chemotherapy, or radiation therapy)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Objective Response Rate - Part 1

Timeframe: Part 1 Week 24

Treatment-emergent adverse events

Timeframe: Part 1 Week 24 and Part 2 Week 72

Trial details

NCT IDNCT05349643

SponsorAmMax Bio, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-06-03

View on ClinicalTrials.gov More Pigmented Villonodular Synovitis trials